Clinical Trials
31 trialsAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
SELECT-CAR-NK
Essen Biotech
ACT
AgonOx, Inc.
ProbeTILity
Curacell Holding AB
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
The First Affiliated Hospital with Nanjing Medical University
ABILITY-1
Medicenna Therapeutics, Inc.
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
PILOT
Astellas Pharma Inc
BAH250
Essen Biotech
BAH248
Essen Biotech
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Beijing YouAn Hospital
COREVAX-1
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Beijing YouAn Hospital
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
PANCEP-1
Sahlgrenska University Hospital
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
ATTACK-OG
The Christie NHS Foundation Trust
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
Beijing YouAn Hospital
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NK-EGFR01
Centre Hospitalier Universitaire de Besancon
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Sun Yat-sen University
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
University of Michigan Rogel Cancer Center